Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide

Diabetes Research and Clinical Practice

Volumn 66, Issue SUPPL., 2004, Pages

  Hamaguchi, Tomoya ^a,b   Hirose, Takahisa ^a   Asakawa, Hideki ^a   Itoh, Yoshiharu ^a   Kamado, Keiji ^a   Tokunaga, Katsuto ^a   Tomita, Koji ^a   Masuda, Hiroshi ^a   Watanabe, Nobuaki ^a   Namba, Mitsuyoshi ^a,b  

^a Japan   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Extrapancreatic effects; Insulin resistance; Metabolic syndrome; Third generation sulfonylurea

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; IMMUNOREACTIVE INSULIN;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SULFONYLUREA COMPOUNDS;

EID: 9644272642     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.12.012     Document Type: Conference Paper

References (12)

1. A. Haupt, C. Kausch, and D. Dahl Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide Diabetes Care 25 2002 2129 2132
2. R. Kawamori, T. Morishima, M. Kubota, M. Matsuhisa, M. Ikeda, and T. Kamada Influence of oral sulfonylurea agents on hepatic glucose uptake Diabetes Res. Clin. Pract. 28 Suppl 1995 S109 S113
3. E. Draeger Clinical profile of glimepiride Diabetes Res. Clin. Pract. 28 Suppl 1995 S139 S146
4. A.E. Pontiroli, A. Calderara, and G. Pozza Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management Diabetes Metab. Rev. 10 1994 31 43
5. S. Katoh, S. Hata, and M. Matsushima Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - a randomized controlled trial Metabolism 50 2001 414 417
6. K.E. Draeger, K. Wernicke-Panten, H.J. Lomp, E. Schuler, and R. Rosskamp Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide Horm. Metab. Res. 28 1996 419 425
7. S.A. Raptis, E. Hatziagelaki, G. Dimitriadis, K.E. Draeger, C. Pfeiffer, and A.E. Raptis Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man Exp. Clin. Endocrinol. Diabetes 107 1999 350 355
8. D. Overkamp, A. Volk, and E. Maerker Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes Diabetes Care 2002 25
9. T. Tsunekawa, T. Hayashi, and Y. Suzuki Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects Diabetes Care 26 2003 285 289
10. M. Korytkowski, A. Thomas, L. Reid, M.B. Tedesco, W.E. Gooding, and J. Gerich Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes Diabetes Care 25 2002 1607 1611
11. D. Porte Jr. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications Diabetes Metab. Res. Rev. 17 2001 181 188
12. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Geneva, Switzerland: Department of Non-communicable Disease Surveillance, World Health Organization; 1999.